Gastroenterology
Volume 141, Issue 6 , Pages 2047-2055 , December 2011

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

  • Stefan Zeuzem

      Affiliations

    • J. W. Goethe University Hospital, Frankfurt, Germany
    • Corresponding Author InformationReprint requests Address requests for reprints to: Stefan Zeuzem, MD, Johann Wolfgang Goethe University Hospital, Frankfurt, Germany. fax: (49) 696 301 6448
    • ,
  • Tarik Asselah

      Affiliations

    • Service d'Hépatologie, Hôpital Beaujon, Université Diderot-Paris 7, and INSERM U773, CRB3, Clichy, France
    • ,
  • Peter Angus

      Affiliations

    • Austin Hospital, Heidelberg, Victoria, Australia
    • ,
  • Jean–Pierre Zarski

      Affiliations

    • Hôpital Albert Michallon, Grenoble, France
    • ,
  • Dominique Larrey

      Affiliations

    • Hôpital Saint-Eloi, Montpellier, France
    • ,
  • Beat Müllhaupt

      Affiliations

    • University Hospital of Zürich, Zürich, Switzerland
    • ,
  • Ed Gane

      Affiliations

    • Auckland City Hospital, Auckland, New Zealand
    • ,
  • Marcus Schuchmann

      Affiliations

    • University Medical Center Mainz, Mainz, Germany
    • ,
  • Ansgar Lohse

      Affiliations

    • University Hospital Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • Stanislas Pol

      Affiliations

    • Hôpital Cochin, Paris, France
    • ,
  • Jean–Pierre Bronowicki

      Affiliations

    • University Hospital of Nancy, Vandoeuvre-lès-Nancy, France
    • ,
  • Stuart Roberts

      Affiliations

    • Alfred Hospital, Melbourne, Victoria, Australia
    • ,
  • Keikawus Arasteh

      Affiliations

    • Epimed GmbH, Berlin, Germany
    • ,
  • Fabien Zoulim

      Affiliations

    • Hepatology Department, Hospices Civils de Lyon, Lyon University, Lyon, France
    • ,
  • Markus Heim

      Affiliations

    • University Hospital Basel, Basel, Switzerland
    • ,
  • Jerry O. Stern

      Affiliations

    • Boehringer Ingelheim, Ridgefield, Connecticut
    • ,
  • George Kukolj

      Affiliations

    • Boehringer Ingelheim (Canada) Ltd, Laval, Quebec, Canada
    • ,
  • Gerhard Nehmiz

      Affiliations

    • Boehringer-Ingelheim Pharma GmbH & Co KG, Biberach, Germany
    • ,
  • Carla Haefner

      Affiliations

    • Boehringer-Ingelheim Pharma GmbH & Co KG, Biberach, Germany
    • ,
  • Wulf Otto Boecher

      Affiliations

    • Boehringer-Ingelheim Pharma GmbH & Co KG, Biberach, Germany

Received 3 June 2011 ,Accepted 30 August 2011.

References 

  1. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206
  2. Jacobson IM, McHutchison JG, Dusheiko GM, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of phase 3 ADVANCE study (abstr 211). Hepatology. 2010;52(Suppl 1):427A
  3. Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study (abstr LB-2). Hepatology. 2010;52(Suppl 1):401A–402A
  4. Sulkowski MS, Ceasu E, Asselah T, et al. SILEN-C1: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naïve patients with chronic genotype 1 HCV infection (abstr 60). J Hepatol. 2011;54(Suppl 1):S27
  5. Tan H, Rajyaguru S, Wu T, et al. Combination of the NS3/4A protease inhibitor ITMN-191 (R7227) with the active moiety of the NS5B inhibitors R1626 or R7128 enhances replicon clearance and reduces the emergence of drug resistant variants (abstr 1885). Hepatology. 2008;48(Suppl 1):1153A
  6. Lacolla M, Lallos LB, Serra I, et al. A triple combination of direct-acting antiviral agents demonstrates robust anti-HCV activity in vitro (abstr 769). J Hepatol. 2010;52(Suppl 1):S299
  7. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467–1475
  8. Manns MP, Bourlière M, Benhamou Y, et al. Potency, safety and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol. 2011;54:1114–1122
  9. Sulkowski MS, Bourliere M, Bronowicki J-P, et al. SILEN-C2: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype-1 patients with non-response to P/R (abstr 66). J Hepatol. 2011;54(Suppl 1):S30
  10. Larrey D, Lohse A, de Ledinghen V, et al. 4 week therapy with the non-nucleoside polymerase inhibitor BI 207127 in combination with peginterferon-alfa2a and ribavirin in treatment naïve and treatment experienced chronic HCV GT1 patients (abstr 2007). J Hepatol. 2010;52(Suppl 1):S466
  11. Kukolj G, McGibbon GA, McKercher G, et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem. 2005;280:39260–39267
  12. Noureddin M, Rotman Y, Feld J, et al. Effects of ribavirin monotherapy on ALT, HCV viral levels, serum cytokines, and hepatic interferon-stimulated gene expression in chronic hepatitis C (abstr 908). Hepatology. 2010;52(Suppl 1):756A
  13. Bodenheimer HC, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997;26:473–477
  14. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(Suppl 1):S237–S244
  15. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593
  16. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292
  17. Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection—role of patient versus nonpatient factors. Hepatology. 2007;46:1741–1749
  18. Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naïve, genotype 1 HCV subjects (abstr LB-1). Hepatology. 2010;52(Suppl 1):400A–401A
  19. Di Bisceglie AM, Nelson DR, Gane E, et al. VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C: ZENITH study interim results (abstr 1363). J Hepatol. 2011;54(Suppl 1):S540
  20. Lok A, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders (abstr 1356). J Hepatol. 2011;54(Suppl 1):S536
  21. Lawitz E, Rodriguez-Torres M, Denning J, et al. Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA <LOD at Day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study) (abstr 1370). J Hepatol. 2011;54(Suppl 1):S543
  22. McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother. 2008;52:1604–1612
  23. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447–462
  24. Rong L, Dahari H, Ribeiro RM, et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med. 2010;2:30–32
  25. Sane R, Podila L, Mathur A, et al. Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335 (abstr 1236). J Hepatol. 2011;54(Suppl 1):S488
  26. Chowdhury JR, Chowdhury NR, Jansen PLM. Bilirubin metabolism and its disorders. In:  Zakim D,  Boyer TD editor. Hepatology: a textbook of liver disease. 4th ed.. Philadelphia, PA: WB Saunders; 2003;p. 233–270
  27. Huisman MT, Snoeys J, Monbaliu J, et al. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters (abstr 278). Hepatology. 2010;52(Suppl 1):461A
  28. Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology. 2006;44:1324–1332
  29. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004;38(Suppl 2):S90–S97
  30. Fueloep B, Rohde P, Buggisch P, et al. The antiviral efficacy of ribavirin priming (A follow up of 93 patients treated with ribavirin monotherapy followed by standard combination treatment (abstr 980)). Hepatology. 2010;52(Suppl 1):793A

 Watch this article's video abstract and others at http://tiny.cc/j026c.

 This article has an accompanying continuing education activity on page e14. Learning Objective: Upon completion of this CME activity, successful learners will be able to explain details on the design and results of the SOUND-C1 clinical trial (BI 201335, BI 207127 and RBV in treatment-naïve patients with chronic HCV GT-1 infection) and assess the potential for this regimen as a future treatment for this patient population.

 Conflicts of interest The authors disclose the following: S.Z. is a consultant for Abbott Laboratories, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, iTherX, Janssen/Tibotec, Merck, Novartis, Pfizer, Pharmasset, Roche/Genentech, Santaris Pharma, and Vertex Pharmaceuticals. T.A. is a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Novartis, and Roche. J.-P.Z. is a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Roche, Janssen, and Merck/Schering-Plough. D.L. is a consultant for Boerhinger Ingelheim, Bristol-Myers Squibb, Roche, Janssen, Merck, and Cytheris. B.M. is a consultant for MSD, Roche, Janssen, and Gilead Sciences. M.S. is a consultant for Bristol-Myers Squibb and Roche and a speaker for Bristol-Myers Squibb, Falk, Gilead Sciences, Merck, and Roche. A.L. has participated in trials for Boehringer Ingelheim, Roche, MSD, Janssen, and Falk and has received lecture fees from MSD, Roche, and Falk. S.P. is a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, Tibotec/Janssen-Cilag, Gilead Sciences, Roche, Merck/Schering-Plough, and Abbott Laboratories; is a speaker for GlaxoSmithKline, Bristol-Myers Squibb, Boehringer Ingelheim, Tibotec/Janssen-Cilag, Gilead Sciences, Roche, and Schering-Plough; and has received grants from Bristol-Myers Squibb, Gilead Sciences, Roche, and Merck/Schering-Plough. J.-P.B. is a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Novartis, and Roche. F.Z. is a consultant for Janssen, Schering-Plough, and Vertex Pharmaceuticals. M.H. is a consultant for Novartis, MSD, Roche, Jansen, and Gilead Sciences. J.O.S., G.K., G.N., C.H., and W.O.B. are employees of Boehringer Ingelheim. The remaining authors disclose no conflicts.

PII: S0016-5085(11)01248-0

doi: 10.1053/j.gastro.2011.08.051

Gastroenterology
Volume 141, Issue 6 , Pages 2047-2055 , December 2011

Article Tools

* Image Usage & Resolution